Signatera | Natera

From Natera®, a global leader in cell-free DNA testing, Signatera™ RUO is the first individualized pan-cancer circulating tumor DNA platform showing promising results in research studies for monitoring treatment response, detecting minimal residual disease and predicting disease recurrence.1, 2, 3, 4

 

Natera is a leader in non-invasive genetic testing of circulating cell-free DNA (cfDNA) in the blood. Our team is powered by world-class experts in molecular biology and bioinformatics. We have built a suite of highly differentiated tests in the prenatal space despite being a late entrant in some markets (Panorama was fourth to the non-invasive prenatal testing arena, but rose to become a market leader on the strength of its SNP-based approach to identifying aneuploidies and microdeletions). To date, we have run more than a million cfDNA tests, and now we are applying our scientifically and commercially proven technology to oncology. Upon partnering with world-leading cancer research institutes, we pioneered a novel approach to detecting and monitoring ctDNA. Our research has been published in top scientific journals.

 

Currently, the Signatera (RUO) ctDNA technology is for research use only and is not for use in diagnostic procedures.

Sponsored research projects with leading institutions

Our peer-reviewed research

  • Abbosh C. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446–451. (2017)
  • Jamal-Hanjani M. et al. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Annals of Oncology 27, 862-867. (2016)
  • Kirkizlar E. et al. Detection of clonal and subclonal copy-number variants in cell-free DNA from patients with breast cancer using a massively multiplexed PCR methodology. Translational Oncology 8, 407-416. (2015)
  • Babiarz J. et al. Detection of copy number variations in breast cancer samples using single-nucleotide polymorphism-targeted massively multiplexed PCR. Cancer Genetics 207, 287. (2014)

Media highlights

Contact us

References

  1. Abbosh C, et al.   Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution, Nature. 2017 Apr 26;545(7655):446-451.
  2. Andersen C, et al.   Personalized circulating tumor DNA analysis to monitor colorectal cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research; 2018 Apri14-18; Chicago (IL); AACR; 2018. Abstract nr 1590.
  3. Birkenkamp-Demtröder K, et al. Sequencing of plasma cfDNA from patients with locally advanced bladder cancer for surveillance and therapeutic efficacy monitoring [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research; 2018 Apri14-18; Chicago (IL); AACR; 2018. Abstract nr 3653.
  4. Sethi H, et al. Analytical validation of the Signatera™ RUO assay, a highly sensitive patient-specific multiplex PCR NGS-based noninvasive cancer recurrence detection and therapy monitoring assay [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research; 2018 Apri14-18; Chicago (IL); AACR; 2018. Abstract nr 4542.
Back to Top